Thoudam Debraj Singh

Prof. Thoudam Debraj Singh

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in Phytochemistry Reviews
Verified
Journal Article
Closed access
PDF file
PUPriyanka Upadhyay
Priyanka Upadhyay
AGAvijit Ghosh
Avijit Ghosh
VSVijaya Sarangthem
Vijaya Sarangthem
TSThoudam Debraj Singh
Thoudam Debraj Singh

8 March 2022 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
SVSarangthem Vijaya
Sarangthem Vijaya
HSHarshita Sharma
Harshita Sharma
RGRidhima Goel
Ridhima Goel
SGSampa Ghose
Sampa Ghose
RPRang-Woon Park
Rang-Woon Park
TSThoudam Debraj Singh
Thoudam Debraj Singh

30 June 2021 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
VSVijaya Sarangthem
Vijaya Sarangthem
AYAena Yi
Aena Yi
YKYunjae Kim
Yunjae Kim
ARAlnawaz Rehemtulla
Alnawaz Rehemtulla
BLByung-Heon Lee
Byung-Heon Lee
RPRang-Woon Park
Rang-Woon Park
Background: Thermal-responsive self-assembled elastin-like polypeptide (ELP)-based nanoparticles are an emerging platform for controlled delivery of therapeutic peptides, proteins and small molecular drugs. The antitumor effect of bioengineered chimeric polypeptide AP1-ELP-KLAK containing an interleukin-4 receptor (IL-4R) targeting peptide and pro-apoptotic peptide (KLAKLAK) was evaluated in glioblastoma (GBM) in vitro and in vivo. Methods and Results: Herein, the therapeutic effect of AP1-ELP-KLAK was tested in advanced, and less curable glioblastoma cells with higher expression of IL-4R. Glioblastoma cell lines stably expressing different reporter systems i.e., caspase-3 sensor (surrogate marker for cellular apoptosis) or effluc/enhanced firefly luciferase (cellular viability) were established to measure cell death non-invasively. Bioluminescence imaging (BLI) of D54/effluc and U97MG/effluc treated with AP1-ELP-KLAK exhibited higher cell death up to 2∼ 3-fold than the control. Treatment with AP1-ELP-KLAK resulted in time-dependent increase of caspase-3 sensor BLI activity in D54/C cells and D54/C tumor-bearing mice. Intravenous injection of AP1-ELP-KLAK dramatically reduced tumor growth by inducing cellular apoptosis in D54/effluc tumor-bearing mice. Further, the immuno-histological examination of the excised tumor tissue confirmed the presence of apoptotic cells as well as caspase-3 activation. Conclusion: Collectively, AP1-ELP-KLAK effectively induced cellular apoptosis of glioblastoma cells and non-invasive imaging provides a window for real-time monitoring of anti-tumor effect with the provision of improving therapeutic efficacy in a glioblastoma mice model.

18 December 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
DGDeepak Gulwani
Deepak Gulwani
PUPriyanka Upadhyay
Priyanka Upadhyay
RGRidhima Goel
Ridhima Goel
VSVijaya Sarangthem
Vijaya Sarangthem
TSThoudam Debraj Singh
Thoudam Debraj Singh
Thyroid cancer (TC) being the common endocrine malignancy is glooming steadily due to its poor prognosis. The treatment strategies of surgery, radiotherapy, and conventional chemotherapy are providing unsatisfactory output. However, combination therapy can negotiate the worse prognosis to the better, where chemoradiotherapy, radiotherapy with surgery, or dual chemotherapeutic drugs are being glorified. Chemotherapy includes the use of doxorubicin or taxanes generally with platinum-based drugs viz. cisplatin or carboplatin that are administered alone or along with multitarget tyrosine kinase inhibitors viz. Lenvatinib, Sorafenib, Sunitinib, Vandetanib, Pyrazolo-pyrimidine compounds, etc., single target tyrosine kinase inhibitors like Dabrafenib plus Trametinib and Vemurafenib against BRAF, Gefitinib against EGFR, Everolimus against mTOR, vascular disruptors like Fosbretabulin, and immunotherapy with viz. Spartalizumab and Pembrolizumab, are anti-PD-1/PD-L1 molecules. Hence, several trials are currently evaluating the possible beneficial role of combinatorial therapy in TC. Since TC is the outcome of multiple genetic alterations, it necessitates targeting the multiple factors in a single shot. These combination strategies for systemically delivering therapeutic drugs seem feasible only with the help of theranostic. To date, nanoparticle-based drug delivery systems (NDDS) have devoted themselves to diagnosis, bioimaging, imaging-assisted surgery, and therapy with high success rates. The ease of handling hybrid technologies is also selectively admirable. However, in this review, we have summarized the sequential progression of chemotherapeutic drugs to NDDS designed for Personalized Medicine (PM) against TC. Personalized medicine is an ever-growing field that will be explored in future discoveries in biomedicine, particularly cancer theranostics. Hence, our review presents a closer view of NDDS as a personalized treatment for TC. We have also discussed the primary challenges facing NDDS in meeting excellence in PM.

13 February 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
RGRidhima Goel
Ridhima Goel
DGDeepak Gulwani
Deepak Gulwani
PUPriyanka Upadhyay
Priyanka Upadhyay
SVSarangthem Vijaya
Sarangthem Vijaya
TSThoudam Debraj Singh
Thoudam Debraj Singh

1 February 2023 in Cells
Verified
Journal Article
Open access
PDF file
TSThoudam Debraj Singh
Thoudam Debraj Singh
JLJae Eon Lee
Jae Eon Lee
KSKwang Hee Son
Kwang Hee Son
BLBo Ra Lee
Bo Ra Lee
SKSang Kyoon Kim
Sang Kyoon Kim
YJYong Hyun Jeon
Yong Hyun Jeon
Previously, we reported that an inverse agonist of estrogen-related receptor gamma (ERRγ), GSK5182, enhances sodium iodide (Na+/I−) symporter (NIS) function through mitogen-activated protein (MAP) kinase signaling in anaplastic thyroid cancer cells. This finding helped us to further investigate the effects of GSK5182 on NIS function in papillary thyroid cancer (PTC) refractory to radioactive iodine (RAI) therapy. Herein, we report the effects of ERRγ on the regulation of NIS function in RAI-resistant PTC cells using GSK5182. RAI-refractory BCPAP cells were treated with GK5182 for 24 h at various concentrations, and radioiodine avidity was determined with or without potassium perchlorate (KClO4) as an NIS inhibitor. We explored the effects of GSK5182 on ERRγ, the mitogen-activated protein (MAP) kinase pathway, and iodide metabolism-related genes. We examined whether the MAP pathway affected GSK5182-mediated NIS function using U0126, a selective MEK inhibitor. A clonogenic assay was performed to evaluate the cytotoxic effects of I-131. GSK5182 induced an increase in radioiodine avidity in a dose-dependent manner, and the enhanced uptake was completely inhibited by KClO4 in BCPAP cells. We found that ERRγ was downregulated and phosphorylated extracellular signal-regulated kinase (ERK)1/2 was upregulated in BCPAP cells, with an increase in total and membranous NIS and iodide metabolism-related genes. MEK inhibitors reversed the increase in radioiodine avidity induced by GSK5182. Clonogenic examination revealed the lowest survival in cells treated with a combination of GSK5182 and I-131 compared to those treated with either GSK518 or I-131 alone. We demonstrate that an inverse agonist of ERRγ, GSK5182, enhances the function of NIS protein via the modulation of ERRγ and MAP kinase signaling, thereby leading to increased responsiveness to radioiodine in RAI-refractory papillary thyroid cancer cells.